1.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
2.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Ang...
by Dahlöf, Björn
The Lancet (British edition), 2005-09-10, Vol.366 (9489), p.895-906
3.
Overweight and obesity: a review of their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America
by Aballay, Laura R
Nutrition reviews, 2013-03, Vol.71 (3), p.168-179
4.
Technologies for global health
by Howitt, Peter, MA
The Lancet (British edition), 2012, Vol.380 (9840), p.507-535
5.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
by Holdaas, Hallvard
The Lancet (British edition), 2003, Vol.361 (9374), p.2024-2031
6.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
by Van Gaal, Luc F
The Lancet (British edition), 2005, Vol.365 (9468), p.1389-1397
7.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
by Ettehad, Dena, MSc
The Lancet (British edition), 2015, Vol.387 (10022), p.957-967
8.
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
by Ridker, Paul M, MD
The American heart journal, 2011, Vol.162 (4), p.597-605
9.
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
by Gæde, Peter
Diabetologia, 2016-08-16, Vol.59 (11), p.2298-2307
10.
HDL and cardiovascular disease
by Rader, Daniel J, Prof
The Lancet (British edition), 2014, Vol.384 (9943), p.618-625
11.
State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease
by Cohen, Beth E
American journal of hypertension, 2015-11, Vol.28 (11), p.1295-1302
12.
Triglycerides and cardiovascular disease
by Nordestgaard, Børge G, Prof
The Lancet (British edition), 2014, Vol.384 (9943), p.626-635
13.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
by Gansevoort, Ron T, Dr
The Lancet (British edition), 2013-07-27, Vol.382 (9889), p.339-352
14.
Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
by Nick Boon
Heart (British Cardiac Society), 2014-04, Vol.100 (Suppl 2), p.ii1-ii67
15.
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
by Stuenkel, Cynthia A
The journal of clinical endocrinology and metabolism, 2015-11, Vol.100 (11), p.3975-4011
16.
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-...
by Poulter, Neil R
The Lancet (British edition), 2005-09-10, Vol.366 (9489), p.907-913
17.
Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery
by Bouri, Sonia
Heart (British Cardiac Society), 2014-03, Vol.100 (6), p.456-464
18.
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
by Windecker, Stephan
The American heart journal, 2017-02, Vol.184, p.81-87
19.
Non-communicable diseases in the Arab world
by Rahim, Hanan F Abdul, Dr
The Lancet (British edition), 2014, Vol.383 (9914), p.356-367
20.
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
by Ridker, Paul M, Prof
The Lancet (British edition), 2012, Vol.380 (9841), p.565-571
